LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Pooled Saliva Testing for COVID-19 Could Expand SARS-CoV-2 Testing Capacity

By LabMedica International staff writers
Posted on 21 Apr 2021
Print article
Illustration
Illustration
A new study supports the expansion of SARS-CoV-2 testing capacity by pooling saliva samples, an approach that can provide cost benefits to laboratories.

Researchers at the Yale School of Public Health (New Haven, CT, USA) analyzed the sensitivity of different numbers of saliva samples pooled together and found that although test sensitivity decreases, the pooled method may provide a more cost-effective method for SARS-CoV-2 testing. When conducting pooled testing, a negative result for an entire pool would indicate that all samples were below the limit of detection, but a positive result for the pool would lead to individual retesting of all samples.

Throughout the pandemic, the use of nasopharyngeal swabs as the standard testing method has presented both a logistical barrier - as they must be collected by trained personnel - but also a supply chain issue, since testing reagents and swabs are in low supply in certain areas. SalivaDirect, a set of open-source testing protocols developed at the School of Public Health which has been issued an Emergency Use Authorization from the US Food and Drug Administration, completely circumvents the complications of using nasopharyngeal swabs. Instead, it applies the RT-qPCR technique to saliva samples, driving down costs and decreasing stress on supply chains.

For their study, the researchers sought to go one step further in decreasing the cost of testing - pooling saliva samples in order to test multiple people simultaneously. The team used saliva collected from COVID-19 inpatients and at-risk healthcare workers. They then analyzed the saliva samples in pools of three different sizes - five, 10 and 20 samples per pool. They discovered that detection sensitivity, a test’s ability to designate an individual with disease as positive, decreased as pool size increased. With the pools of five samples, the sensitivity was reduced by 7.4%, as compared to testing on an individual sample. For 20-sample pools, there was a 14.8% reduction in this value. However, decreased sensitivity is expected with pooling samples, and the researchers concluded that this level of sensitivity could still be effective for accurate, large-scale screening of SARS-CoV-2.

The researchers also pointed out that the lower per-person cost of pooled testing may allow for more frequent testing, and thus a lower probability of two repeated false-negative results for any one person. In this way, pooling samples can be even more effective than individual testing, according to the study. In the future, the researchers hope to analyze the implementation of pooled testing to see if it actually helps communities reduce costs while adequately screening the members of the community. In doing so, researchers will be able to see the effects of pooled testing with a larger sample size than in their studies.

“Pooling is essential,” said Anne Wyllie, Associate Research Scientist in Epidemiology and researcher at the Yale School of Public Health. “We need to find ways to do mass testing that is affordable and can be widely accessible. Pooling is a natural strategy to bring test prices down and to test more samples overall.”

“Even though we might get a drop in sensitivity with pooling, depending on the prevalence in the particular environment in the particular population, it will still end up being a lot cheaper and very beneficial,” added Orchid Allicock, Postdoctoral Research Associate at the School of Public Health.

Related Links:
Yale School of Public Health

Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Vaginitis Test
Allplex Vaginitis Screening Assay
New
Bordetella Pertussis Molecular Assay
Alethia Pertussis

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.